REDHILL BIOPHARMA LTD-SP ADR (RDHL) Stock Price, Quote, News and Overview
NASDAQ:RDHL - Nasdaq - US7574683014 - ADR - Currency: USD
RDHL Quote, Performance and Key Statistics
4.76
-0.14 (-2.86%)
The current stock price of RDHL is 4.76 USD. In the past month the price decreased by -27.16%. In the past year, price decreased by -64.57%.
RDHL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.62 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About RDHL
Company Profile
Redhill Biopharma Ltd is a IL-based company operating in Pharmaceuticals industry. RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Company Info
REDHILL BIOPHARMA LTD-SP ADR
21 Ha'arba'a St.
TEL AVIV-YAFO 64739 IL
CEO: Dror Ben-Asher
Employees: 53
Company Website: https://www.redhillbio.com/
Investor Relations: https://ir.redhillbio.com/
Phone: 97235413131
REDHILL BIOPHARMA LTD-SP ADR / RDHL FAQ
What is the stock price of REDHILL BIOPHARMA LTD-SP ADR today?
The current stock price of RDHL is 4.76 USD. The price decreased by -2.86% in the last trading session.
What is the ticker symbol for REDHILL BIOPHARMA LTD-SP ADR stock?
The exchange symbol of REDHILL BIOPHARMA LTD-SP ADR is RDHL and it is listed on the Nasdaq exchange.
On which exchange is RDHL stock listed?
RDHL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for REDHILL BIOPHARMA LTD-SP ADR stock?
7 analysts have analysed RDHL and the average price target is 19380 USD. This implies a price increase of 407042.86% is expected in the next year compared to the current price of 4.76. Check the REDHILL BIOPHARMA LTD-SP ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is REDHILL BIOPHARMA LTD-SP ADR worth?
REDHILL BIOPHARMA LTD-SP ADR (RDHL) has a market capitalization of 6.10M USD. This makes RDHL a Nano Cap stock.
How many employees does REDHILL BIOPHARMA LTD-SP ADR have?
REDHILL BIOPHARMA LTD-SP ADR (RDHL) currently has 53 employees.
What are the support and resistance levels for REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?
REDHILL BIOPHARMA LTD-SP ADR (RDHL) has a resistance level at 5.28. Check the full technical report for a detailed analysis of RDHL support and resistance levels.
Is REDHILL BIOPHARMA LTD-SP ADR (RDHL) expected to grow?
The Revenue of REDHILL BIOPHARMA LTD-SP ADR (RDHL) is expected to grow by 131.11% in the next year. Check the estimates tab for more information on the RDHL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RDHL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RDHL, evaluating the profitability, health, valuation and growth aspects
- REDHILL BIOPHARMA LTD-SP ADR (RDHL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- REDHILL BIOPHARMA LTD-SP ADR (RDHL) Sales and EPS estimates to see what analysts future expectations are.
- REDHILL BIOPHARMA LTD-SP ADR (RDHL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- REDHILL BIOPHARMA LTD-SP ADR (RDHL) Insider and Institutional Ownership to learn about the owners and their transactions.
- REDHILL BIOPHARMA LTD-SP ADR (RDHL) Stock Chart to make your own analysis
- REDHILL BIOPHARMA LTD-SP ADR (RDHL) Latest news and press-releases to stay up to date.
Does REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock pay dividends?
RDHL does not pay a dividend.
What is the Price/Earnings (PE) ratio of REDHILL BIOPHARMA LTD-SP ADR (RDHL)?
The PE ratio for REDHILL BIOPHARMA LTD-SP ADR (RDHL) is 0. This is based on the reported non-GAAP earnings per share of 2119.18 and the current share price of 4.76 USD. Check the full fundamental report for a full analysis of the valuation metrics for RDHL.
What is the Short Interest ratio of REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?
The outstanding short interest for REDHILL BIOPHARMA LTD-SP ADR (RDHL) is 166.52% of its float. Check the ownership tab for more information on the RDHL short interest.
RDHL Technical Analysis
RDHL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RDHL. RDHL has a medium profitability rating, but doesn't score so well on its financial health evaluation.
RDHL Financial Highlights
Over the last trailing twelve months RDHL reported a non-GAAP Earnings per Share(EPS) of 2119.18. The EPS increased by 292.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 366.25% | ||
| ROA | 108.59% | ||
| ROE | 39206.56% | ||
| Debt/Equity | 3.11 |
RDHL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to RDHL. The Buy consensus is the average rating of analysts ratings from 7 analysts.